ETHK Labs Profit Slumps 86% as Competition and Expansion Costs Bite

The latest announcement is out from IVD Medical Holding Limited ( (HK:1931) ).

ETHK Labs Inc. reported a challenging 2025, with revenue falling 10.8% year-on-year to RMB2.82 billion and gross profit dropping 24.6%, reflecting intensifying competition in the IVD market. Net profit declined sharply by 85.9% to RMB37.4 million, and basic earnings per share slid to 2.16 RMB cents, prompting the board to withhold a final dividend.

Management attributed the earnings deterioration not only to the tougher operating environment but also to higher administrative costs tied to its newly launched AI business and increased finance expenses from additional borrowings for expansion and working capital. The weak results and absence of a dividend signal near-term pressure on shareholder returns as the company invests in new technology and capacity to reposition itself in a more competitive diagnostic landscape.

The most recent analyst rating on (HK:1931) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.

More about IVD Medical Holding Limited

ETHK Labs Inc., formerly known as IVD Medical Holding Limited, operates in the in vitro diagnostics (IVD) industry, providing diagnostic products and related services. The Group focuses on the Chinese market, where it has been expanding its business, including a newly launched artificial intelligence (AI) segment to support future growth in medical and diagnostic applications.

Average Trading Volume: 4,307,418

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.82B

For a thorough assessment of 1931 stock, go to TipRanks’ Stock Analysis page.